Articles - Page 59 of 96 - Drugs in Context

Use of anti-CD20 therapy in follicular and marginal zone lymphoma: a review of the literature

Luis Miguel Juárez-Salcedo MD, Diego Conde-Royo MD, Keina Quiroz-Cervantes MD, Samir Dalia MD

Article Type

Review

Published

06 May 2020

This article discusses the role of mAbs in follicular lymphoma and marginal zone lymphoma along with reviewing the current data about the use of biosimilar mAbs in these diseases.

Conjunctivitis in patients with atopic dermatitis treated with dupilumab

Sandra Ferreira MD, Tiago Torres MD, PhD

Article Type

Review

Published

04 May 2020

The present paper reviews the data of dupilumab-associated conjunctivitis and risk factors in adults with moderate-to-severe AD and other atopic diseases in dupilumab clinical trials and addresses the characteristics and treatment options available for this clinically highly relevant condition.

Chloroquine and hydroxychloroquine in the context of COVID-19

Ashutosh M Shukla MD, Lennox K Archibald MD, Aparna Wagle Shukla MD, Hiren J Mehta MD, Kartikeya Cherabuddi MD

Article Type

Review

Published

28 Apr 2020

This review aims to present the available in vitro and in vivo data for the role of chloroquine/ hydroxychloroquine in COVID-19 and attempts to put them into perspective, especially in relation to the different risks/benefits particular to each patient who may require treatment.

Clinical study of the tolerability of calcium carbonate–casein microcapsules as a dietary supplement in a group of postmenopausal women

Santiago Palacios PhD, MD, Marieta Ramirez MD, Mariella Lilue MD

Article Type

Original Research

Published

23 Apr 2020

This article reviews the tolerability of a new delivery system for calcium supplementation, based on the functionalization of calcium carbonate (CaCO3) particles by casein proteins, in a randomized, prospective, double-blind, active comparator clinical trial.

Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors

Keira A Fieldhouse Bsc, Samantha Ukaibe BSc, Erika L Crowley BSc, MSc, Reena Khanna MD, MSc, FRCPC, Ashley O’Toole MD, MHSc, FRCPC, Melinda J Gooderham MD, MSc, FRCPC

Article Type

Review

Published

21 Apr 2020

This paper reviews all incident cases and exacerbations of IBD reported in the literature during widescale use of IL-17 inhibitors beyond the clinical trials.